Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Small Cell Lung Carcinoma 1Mycosis Fungoides 1Multiple Myeloma 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Inflammatory Breast Neoplasms 1Hodgkin Disease 1Esophageal Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1

Interventions

Trastuzumab 3Taxes 3Radiotherapy 3Paclitaxel 3Cyclophosphamide 3Epirubicin 2Doxorubicin 2Docetaxel 2Biopsy 2trastuzumab biosimilar HLX02 1talimogene laherparepvec 1romidepsin 1pertuzumab 1pembrolizumab 1pegfilgrastim 1nintedanib 1neratinib 1grapiprant 1eribulin 1caficrestat 1bemcentinib 1Tamoxifen 1Razoxane 1Radiation 1PF-05280014 1Ontruzant 1Ogivri 1Nivolumab 1Neoadjuvant Therapy 1Lapatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Inflammatory Breast Neoplasms × Depsipeptides × Clear all
NCT01938833 2025-05-16

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Thomas Jefferson University

Phase 1/2 Terminated
9 enrolled 7 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡